# Mounjaro

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/mounjaro
Canonical HTML page: https://gethealthbrief.com/entity/mounjaro

## Recent coverage (1 stories)

### Lilly’s Triple-G Retatrutide Hits Phase 3 Diabetes Goal, Lags Mounjaro Slightly
2026-03-19 11:58:18 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
Full story: https://gethealthbrief.com/story/lilly-triple-g-phase-3-diabetes-data

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.